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Abstract
The human body is made up of trillions of cells. Although all the human body cells contain the same DNA
sequence inside their nuclei, each one carries out its own function. Normally, human cells grow and
divide to form daughter cells as the body needs them. When cells grow old, or lose their ability to function
properly, they die (in a very organized way called apoptosis or programmed cell death) and new cells
take their role. Cancer is a disease that is caused by uncontrolled division of abnormal cells in some part
of the body, breaking the natural process of growing. Old or damaged cells survive when they should die,
and new (abnormal) cells form when they are not needed. Some types of cancer form solid tumors,
which are masses of tissue. Others, such as leukemias, do not form solid tumors. It is widely believed
that cancer is caused by the accumulation of detrimental variation in the genome over the course of a
lifetime. Variations can take several forms. Single Nucleotide Polymorphism (SNP) is a mutation in a
single base of the DNA. Indels describe insertions or deletions of bases in the genome. Copy Number
Variation (CNV) represents multiplied and deleted segments in a genome. Most of the time, one type of
mutation is not sufficient to induce cancer formation.
In this study, we have investigated genomic datasets of a phase-1 clinical trial on triple-negative breast
cancer and ovarian cancer patients. The goal is to identify genes that drive drug resistance. We have
developed data analysis pipelines to obtain genomics variations (somatic mutations and copy number
variations) from the Whole Exome Sequencing (WES) raw data of 35 triple-negative breast cancer
(TNBC) and ovarian cancer patients. In addition, we have analyzed the gene expression levels and gene
fusion from the RNA-Seq raw reads data for a subset of 16 patients. This study is an effort toward
optimizing the integrative analysis of genomic datasets under certain limitations. The main limitation is
the small number of samples in the clinical trial (as is the case in most clinical trials). Another challenge
is to find an abstract way to analyze the raw sequencing data given its large size and heterogeneity. The
novelty of our work comes in following a data science approach in answering such research questions.
The unbiased and data-driven approach was successful in identifying genes that are most likely related
to the drug resistance. Our results will guide clinicians toward having an in-depth study of the driver
genes.

ix

Chapter 1: Introduction
The human body is made up of trillions of cells. Although all human body cells contain the same
DNA sequence inside their nuclei, each one carries out its own function. Normally, human cells grow and
divide to form daughter cells as the body needs them. When cells grow old, or lose their ability to function
properly, they die (in a very organized way called apoptosis or programmed cell death) and new cells
take their role. Cancer is a disease that is caused by uncontrolled division of abnormal cells in some part
of the body, breaking the natural process of growing [1]. Old or damaged cells survive when they should
die, and new (abnormal) cells form when they are not needed. Some types of cancer form solid tumors,
which are masses of tissue. Others, such as leukemias, do not form solid tumors.

The Cancer
Cancer Research UK studies show that 8.2 million people died in 2012 worldwide because of
cancer [2]. Worldwide, breast cancer accounts for nearly a quarter of all cancers in women and it is
estimated that 1.7 million women are diagnosed with the disease annually. Although the incidence rates
of invasive breast cancer have remained stable over the past several decades among women younger
than 50, Figure 1 shows substantial changes in rates among women older than 50 years old. Moreover,
Figure 2 shows the rate of metastatic breast cancer at initial diagnosis in the United States. There was
no remarkable change in the rates despite the widespread use of mammography for early detection [3].

Figure 1 - U.S. incidence rates of invasive breast cancer among women <50 and ≥50, 1975-2012

There are two categories of genes that are directly related to cancer. The first category is called
oncogenes, which boost the activity of a cell to grow and divide abnormally. The second category is
tumor-suppressor genes, which kill cells that goes through abnormal division path [1]. Cancer cells either
over-express oncogenes, under-express tumor-suppressor genes or both. It has been revealed that
cancer is caused by an accumulation of detrimental variation in the genome over the course of a lifetime.
Variations can take several forms. Single Nucleotide Polymorphism (SNP) is a variation in a single base

1

of the DNA. Indels describe insertions or deletions of bases in a genome. Most of the time, a single
mutation is not sufficient to induce cancer formation. Larger regions of mutations in the DNA lead to the
dysfunction (over-expression or under-expression) of genes (oncogenes or tumor-suppressor genes) that
ultimately cause cancer.

Figure 2 - Female Breast Cancer Incidence Rates by Stage, US, 1975-2012

Triple-Negative Breast Cancer (TNBC) and High Grade Serous Ovarian
Cancer
In this work, we focus our efforts on one type of breast cancer called Triple-Negative Breast
Cancer (abbreviated TNBC) and its closely similar cancer, ovarian cancer [4]. TNBC refers to any type of
breast cancer that does not express the genes for estrogen receptors (ER), progesterone receptors (PR)
or HER2/neu receptors. HER2 is a type of oncogenes that is overexpressed in some types of breast
cancer (ER negative, PR negative and HER2 negative). That’s why it is called triple negative. This
classification leads to therapeutic implications because patients cannot benefit from endocrine therapy as
it lacks ER and PR. In addition, they cannot benefit from Anti-HER2 agents since it is HER2 negative.
This makes it more difficult to treat as most chemotherapies target one of the three receptors, so it
requires a combination of therapies [5].
According to [6], TNBC accounts for 12-17% of all breast cancers. It is more prevalent in younger
women (< 50 years) and African and Hispanic descent. There is a huge enrichment for tumors of the
triple negative phenotype in the subset of patients with BRCA1 germline mutations. BRCA1 is considered
as a tumor-suppressor gene responsible for the DNA repair, and a mutation in it causes immature
daughter cells at cell replication. The same study showed that 80%-85% of BRCA1 breast cancers are
triple negative and 10%-14% of TNBCs harbor BRCA1 mutations. TNBCs span from low grade tumors to
high grade tumors. Similarly, the study in [7] revealed that 1.5% of women will be diagnosed with ovarian
cancer. A woman with a mutation in the BRCA1 gene has a 40–60% lifetime risk of developing ovarian
cancer [8]. For BRCA2 the lifetime risk is lower at 10–30%. However, it is still around a 10-fold higher risk
than for the general population.

2

The huge heterogeneity remains a challenge when it comes to the histological features of TNBCs
and ovarian cancers. First generation prognostic signatures, such as molecular classification,
invasiveness gene signatures or tumor size, are of no use for triple negative disease [9]. That is because
these first-generation prognostic signatures are nothing but feature counters. They identify tumors as of
prognosis on the basis of high-expression levels of proliferation-related genes. Given that 97% of TNBC
and 80% of ovarian cancers have high-expression levels of proliferation-related genes [10,11], they offer
no discriminatory power.

The Datasets
We have sequencing data from a Phase I clinical trial study of the Oral PI3kinase-inhibitor (NVPBKM120) in combination with the Oral PARP-inhibitor (Olaparib) in patients with recurrent Triple
Negative Breast Cancer or High Grade Serous Ovarian Cancer. Whole exome sequencing (WES) data
of 35 patients from this study are available. There were a number of long-term responders to the regimen
(> 6 months), raising the question as to what the genomic profile of the tumors that did respond was.
RNAseq data of 8 responders and 8 non-responders of these 35 patients are also available. In summary,
we have the following datasets:




DNA sequencing data.
o WES of 35 tumors and their match normal samples
RNA sequencing data.
o RNA-Seq of 16 tumors (8 responders and 8 non-responders) and 5 normal control
Clinical data
o Drug response of sensitive and resistant groups.

Source: Dr. Gerburg Wulf from BIDMC and Harvard Medical School provided WES and samples for
RNA-Seq. RNA-Seq data have been generated by the CGI at UConn. All datasets are stored on UConn
BBC HPC cluster [12].

Related Work
To understand the mechanism of cancer, biomedical researchers are interested in identifying genomic
aberrations that promote cancer development, known as drivers. They are also interested in profiling
gene expression data to understand disease pathogenesis. It is hypothesized that driver genes involved
in resistance likely have aberrant copy numbers and/or mutations and that the expression patterns of
these genes match the mutation and copy number patterns [13]. The genomic aberrations, incorporated
with gene expression profiles in disease progression, has motivated several studies. Huang N. et. al.
have shared lessons extracted from over ten years of performing integrative analysis on cancer data [14].
Several methods have been used to integrate gene expression and CNV data. In general, these
methods are based on three main approaches: 1-regression, 2-correlatin, and 3-module network. Linear
approaches, such as regression analysis or correlation analysis, do not work properly for heterogeneous
data that their within-group variations are extremely high, such as ovarian cancer data. Further, in
general, the relationship between gene expression and structural variations is not linear.
Kristensen V. et. al. surveyed the existing computational methodologies that are being used to assess
cancer genomic data in [15]. In addition to the many tools surveyed, the review has assured that a more
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fundamental understanding of the biological dynamics of cancer will enable us to better identify risk
factors and refine cancer diagnosis. We can also predict therapeutic effects and prognosis, and identify
new targets for therapy. The integrative analysis of genomic datasets introduced a paradigm shift from
large randomized clinical trials towards treatment modalities that are tailored for stratified patient groups,
down to N-of-1 trials, in which data from a single patient represents an entire trial.
It has been shown that the module network analysis, which is a non-linear approach, performs well in
identifying driver genes in cancer [16]. In [17], Nabavi S. has employed the module network analysis
upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. The module
network analysis is a form of Bayesian network analysis. However, similarly behaving variables (genes)
can be grouped into modules (a group of genes) and that the network can learn the same parents and
parameters for each module, instead of each variable, as in a Bayesian network. The main motivation for
using module network analysis instead of regular Bayesian network analysis is that biological systems,
similar to all complex systems, have too many variables but not enough data to robustly learn networks.
In biological systems, we have thousands of genes but few samples. In addition, large networks are
difficult to interpret, especially in biological systems. Moreover, it is assumed that genes that are coexpressed are likely regulated in similar ways and might have the same drive. The study performed using
module network analysis yielded a short list of aberrant genes that control the expression of their coregulated genes. Although the method introduced was successful, we could not utilize it in our study
since the number of samples we have is very small. In order to identify candidate biomarkers, we had to
employ techniques that perform better in our situation.
Jennings E. et. al. performed an integrated analysis of heterogeneous genomic data using a hierarchical
Bayesian analysis framework [18]. The framework incorporated the biological relationships among the
different types of data to identify genes whose expression is related to clinical outcomes in cancer. This
integrated approach lead to increased statistical power in finding these predictive genes, and further
provided mechanistic information about the manner in which the gene affects the outcome. The study
found 12 positive prognostic markers associated with nine genes and 13 negative prognostic markers
associated with nine genes.
In [19], Wang W. et. al. proposed and implemented an integrative Bayesian analysis of genomics data
(iBAG) framework for identifying important genes/biomarkers that are associated with clinical outcome.
This framework also used the hierarchical modeling approach to combine the heterogeneous data
obtained from multiple platforms into one model. The performance of our methods using several
synthetic and real examples showed that the integrative methods have a higher power to detect diseaserelated genes than non-integrative methods. The methods were applied on the Cancer Genome Atlas
glioblastoma dataset. The iBAG model integrated gene expression and methylation data to study their
associations with patient survival. It discovered multiple methylation-regulated genes that are related to
patient survival, most of which have important biological functions in other diseases but have not been
previously studied in glioblastoma.
Although the aforementioned studies slightly differ in their approaches and implementation, they share a
common integrative analysis characteristic. In our study, we present a data science approach toward
achieving the same goal of identifying candidate biomarkers for clinical outcomes.
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Chapter 2: Genomic Features
In this chapter, we cover important terminologies that we will use frequently in the subsequent
chapters. We first start with basic definitions. Then, we discuss genomic features that will be the focus of
our data analysis work.

Basic Definitions
The Body Cell
A cell is the smallest unit of a living organism. It is made up of many even smaller parts, each with its
own function. Human cells vary in size, but all are small and cannot by seen by the naked eye. Figure 3
shows a breakdown of the human cell. The membrane holds the contents together. It also has receptors
that bind to the signal molecules and communicate its presence inward into the cell. The receptors also
react to substances produced in the body and to drugs taken into the body, selectively allowing these
substances or drugs to trigger the cell functions. Reactions that take place at the receptors often alter or
control a cell's functions. Within the cell membrane are two major components [20]:



The cytoplasm: contains structures that consume and transform energy and perform the cell's
functions.
The nucleus: contains the cell's genetic material (DNA) and the structures that control cell division
and reproduction.

Figure 3 - Human Cell. Credit: edited from RuguSavay.com

The DNA
The DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms.
Every cell in a person’s body has the same DNA. It is located in the cell nucleus where it is divided into
chromosomes. In humans, the DNA is divided into 23 pairs of chromosomes. The information in DNA is
stored as a code made up of four chemical bases: adenine (A), cytosine (C), guanine (G), and thymine
(T). Human DNA consists of about 3 billion of these bases. The order, or sequence, of these bases
determines the information available for building and maintaining an organism, similar to the way in
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which letters of the alphabet appear in a certain order to form words and sentences. As shown in Figure
4, the DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone [21].

Figure 4 - DNA Structure. Credit: U.S National Library of Medicine

Genes
A gene is a region (or a set of non-overlapping regions) of the DNA that encodes for part of the cell
functions. Each chromosome contains many genes. Genes act as instructions to make molecules called
proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases.
Each gene consists of coding regions (exons) and non-coding regions (introns). The Human Genome
Project has estimated that humans
have between 20,000 and 25,000
genes [22]. Every person has two
copies of each gene, one inherited
from each parent. Most genes are
the same in all people, but a small
number of genes (less than 1
percent of the total) are slightly
different between people. These
differences contribute to each
person’s unique physical features.
Gene Expression
The DNA nucleotides

Figure 5 - Genes. Credit: U.S. National Library of Medicine

remain

6

inside the cell’s nucleus. Some of them (genes) get copied to the cytoplasm in a process called gene
expression. The ultimate product of gene expression are functional proteins, which can go on to perform
essential functions as enzymes, hormones and receptors.
Gene expression starts with the transcription process, which copies gene regions from inside the nucleus
to the outside. Transcription starts from a promoter region and ends at a stop codon site. It results in a
pre-messenger RNA (ribonucleic acid). The RNA is represented the same as DNA with letters: A, C, G
and U (uracil, instead of T). The next step involves removing introns from the copied regions in a process
known as splicing. It results in a mature mRNA. After that, the mature mRNA is translated into functional
proteins.

Figure 6 - Gene Expression. Credit: National Institute of Health
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Proteins
Proteins are the ultimate product of the gene expression process. They do most of the work in cells and
are required for the structure, function, and regulation of the body’s tissues and organs. Proteins are
made up of hundreds or thousands of smaller units called amino acids, which are attached to one
another in long chains. There are 20 different types of amino acids that can be combined to make a
protein. The sequence of amino acids determines each protein’s unique 3-dimensional structure and its
specific function. Table 1 shows the genetic code: rules by which information encoded by genetic
material (DNA and RNA) is translated into amino acids (identified from 3-mer sequences) that combined
form a protein.
Table 1 – Genetic Code

Gene Fusion
Due to abnormal cellular activities, two
genes might fuse together at the
transcription process forming a new gene
as shown in Figure 7. This results a
unique protein product at the end that
might lead the cell to function improperly.

Figure 7 - Gene Fusion. Credit: EMC Galaxy Training
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Mutations
Single Nucleotide Polymorphism (SNP)
SNPs are variations in a single base pair in a DNA sequence as shown in Figure 8(a).
Indel
Indels are the insertion or the deletion of bases in the DNA of an organism as shown in Figure 8(b).

Figure 8 - Structural Variations. (a) SNP. Credit: International Society of Genetic Genealogy
(b) Indels. Credit: Hackbright Academy. (c) CNVs. Credit: MindSpec.org

Synonymous vs. Non-synonymous Variations
In fact, not all mutations in the DNA are harmful and cause abnormal activity in the cell. Mutations can
occur in non-coding regions which are not transcribed. Also, as we saw in the protein table previously,
some sequences result in the same protein. Therefore, some variations are synonymous and result in
the same ultimate protein sequence. In our study, we are interested only in non-synonymous variations.
Figure 9shows a classification of variations.

Non-coding
region
Variations

Synonymous
Coding
region

Missense
NonSynonymous
Nonsense

Figure 9 – Types of variations
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Non-synonymous variations of the type Missense results in a change in the protein as in the following
example.
DNA: 5' - AAC AGC CTG CGT ACG GCT CTC - 3'
mRNA: 5' - AAC AGC CUG CGU ACG GCU CUC - 3'
Protein:
Asn Ser Leu Arg Thr Ala Leu


A mutation:

DNA: 5' - AAC AGC CTG CTT ACG GCT CTC - 3'
mRNA: 5' - AAC AGC CUG CUU ACG GCU CUC - 3'
Protein:
Asn Ser Leu Leu Thr Ala Leu
Non-synonymous variations of type Nonsense causes the transcription to in an earlier position than the
mature stop position. The following is an example.
DNA: 5' - ATG ACT CAC CGA GCG CGA AGC TGA - 3'
mRNA: 5' - AUG ACU CAC CGA GCG CGA AGC UGA - 3'
Protein:
Met Thr His Arg Ala Arg Ser Stop


A mutation:

DNA: 5' - ATG ACT CAC TGA GCG CGA AGC TGA - 3'
mRNA: 5' - AUG ACU CAC UGA GCG CGA AGC UGA - 3'
Protein:
Met Thr His Stop

Structural Variations
Some diseases, such as cancer, are caused by structural variations in the DNA [1]. Structural variations
describe changes in the DNA sequence that might lead to a change in the proteins resulting from the
gene expression process. We present the type of variations that we focused on during our study.
Copy Number Variation (CNV)
CNVs are a phenomenon in which parts of the genes are repeated or deleted. The number of
repetition/deletion in the DNA varies between individuals in the human population. Figure 8(c) shows an
example of a deletion on the left and an example of a duplication on the right.

Genetics of Cancer
Cancer is a genetic disease in most cases. It is caused by the abnormal cell division. Cells divide and
grow in the presence of signals that normally inhibit abnormal cell growth [1]. As these cells grow, they
develop new characteristics, including changes in DNA structure. Such changes allow the cancer cells to
spread and invade other tissues, carrying with them their undesired characteristics. The abnormalities in
cancer cells usually result from mutations in protein-encoding genes that regulate cell division. Over time
more genes become mutated. This is mostly because the genes that make the proteins that normally
repair DNA damage are themselves not functioning normally because they are also mutated.
Consequently, mutations begin to increase in the cell, causing further abnormalities in that cell and the
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daughter cells [1]. In cancer, somatic evolution is the accumulation of mutations in the cells of a body
during a lifetime, and the effects of those mutations on the fitness of those cells. Somatic mutations can
occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed
on to children. These alterations can (but do not always) cause cancer or other diseases.
Recall from chapter 1 that our clinical trial investigates the drug response of a the Oral PI3kinaseinhibitor (NVP-BKM120) in combination with the Oral PARP-inhibitor (Olaparib) in patients with recurrent
TNBC and ovarian cancer. In the next chapter, we discuss the data analysis pipelines we have
developed for the whole exome sequencing (WES) and RNA Sequencing.
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Chapter 3: Developing Pipelines for Analyzing High-throughput Data
In this chapter, we present the development stages of our data analysis pipeline. Recall that we are
given whole exome sequencing data for 35 patients and RNA sequencing data for a subset of 16
patients. The next sections illustrate the pipelines in details.

Whole Exome Sequencing
Whole exome sequencing is a technique used for sequencing all the exonic regions of a genome. It
starts by capturing only the regions of the DNA that encodes for proteins (i.e. exons). After that,
instruments such as Illumina HiSeq are used to generate raw data files representing the DNA fragments
(also known as short reads) [23]. Figure 10 shows the sequencing stages. For each patient, we obtained
a sample from a normal tissue and another sample from the tumor tissue, which is the breast in our study.
Then, using DNA templates in a flow cell, exons are extracted from the DNA. After that, a highthroughput sequencer is used to read and interpret the short fragments into representations of the base
pairs: A, C, G and T.

Figure 10 - Whole Exome Sequencing. Credit: Canadian Bioinformatics Workshops

Our study starts from the data analysis pipeline. We are given raw sequencing reads. Figure 11 shows
the steps we have done in the analysis, followed by a detailed illustration of each step. The first two
phases are considered as input to the pipeline. They have been performed under the supervision of Dr.
Gerburg Wulf from BIDMC and Harvard Medical School.
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Sequencing

Raw Reads

• Patient samples
• Illumina
Sequencing

• FASTQ files

Quality
Check
• FASTQ.C

Alignment
• Human
Genome 19
• BWA Aligner

Preprocessing

Variation
Analysis

• Sorting
• Indexing
• Pileup

• Somatic
Mutation
• CNV

Annotation
• Gene Names

Figure 11 – Whole Exome Sequencing (WES) pipeline

Raw Reads
Data from sequencing comes in raw text files in FASTQ format [24]. A FASTQ file normally uses four
lines per sequence. Line 1 begins with a '@' character and is followed by a sequence identifier and an
optional description. Line 2 is the raw sequence letters, which came in lengths of 100 base pairs in our
study. Line 3 begins with a '+' character and is optionally followed by the same sequence identifier (and
any description) again. Line 4 encodes the quality values for the sequence in Line 2, and must contain
the same number of symbols as letters in the sequence. For example, A FASTQ file containing a single
sequence looks like this:
@SEQ_ID
GATTTGGGGTTCAAAGCAGTATCGATCAAATAGTAAATCCATTTGTTCAACTCACAGTTT
+
!''*((((***+))%%%++)(%%%%).1***-+*''))**55CCF>>>>>>CCCCCCC65
The quality values are encoded using Phred quality scores. Phred quality scores are assigned to each
nucleotide base call in automated sequencer traces. They have become widely accepted to characterize
the quality of DNA sequences [24]. The quality scores become very important in the next step of the
quality check.
For each patient, we have received two sets of FASTQ files: files for normal tissue and files for the tumor
tissue. The total size of all FASTQ files for all 35 patients is ~700 GB in a gzip compressed format. For
the next pipeline phases, Linux scripts are provided for each task on the project’s GitHub repository [25].
Quality Check
The current sequencing technologies produce errors in the read files. That’s why the quality score line is
included in the FASTQ file for each read. In order to guarantee reliable results by the end of the analysis,
we checked the quality of all FASTQ files using FASTQC v0.11.2 [26]. The summary reports showed no
potential errors or warnings. Figure 12 shows an example of the report generated by the tool for one of
the patients. Complete quality reports for all patients can be found on the project’s GitHub repository
under variation-analysis folder.
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Figure 12 - Per base sequence quality for one of the samples

Alignment to the human genome
Since the short reads are not in a
specific order in the file, the next
step in the pipeline is to map them to
the human genome. Figure 13
visualizes the reference genome in
the top track and the short read
mapping below it. The blue lines
connect the pair-end reads. Red
bars are the short reads. For the
alignment, we have used the
Burrows-Wheeler
Aligner
tool
v0.7.12-r1039 [27] and mapped the
reads to the human genome
reference (Hg19) downloaded from
UCSC genome browser [28].

Figure 13 - Short read alignment to the human genome. Credit: Wikipedia
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Aligning each patient’s samples separately, we obtain two alignment files: one for normal and one for
tumor. The alignment files are in SAM format (Sequence Alignment/Map) [29]. It is a TAB-delimited text
format consisting of a header section, which is optional, and an alignment section. If present, the header
must be prior to the alignments. Header lines start with ‘@’, while alignment lines do not. Each alignment
line has 11 mandatory fields for essential alignment information such as mapping position, and variable
number of optional fields for flexible or aligner specific information. The total size of all SAM files for all
35 patients is ~3.5 TB.
Preprocessing
Before starting to analyze the alignment files for variation analysis, it is of great benefit to pre-process the
data for future operations to take less time. Preprocessing includes sorting and indexing the aligned
reads and converting the results to fixed binary files for faster analysis. For this task, we have used
Picard v2.3.0 included in the GATK framework [30] following the best practices described in [31] and [32].
This reduced the size of our files to ~2.6 TB of processed alignment files along with indices.
Somatic Variation Analysis
In this step of the pipeline, we have analyzed the processed files in order to identify somatic variations.
To achieve this, we perform a per-patient analysis comparing the patient’s normal file with the tumor file.
SNPs as well as Indels. In this analysis, variations are identified for each patient with relative to her
normal sample (not with the reference human genome). For this phase, we have used VarScan2 v2.4.2
[33] with some intermediate steps done using SAMtools v1.2 and htslib v1.2.1 [29].
This phase results in the variations for each patient separately in VCF format (Variant Call Format) [34].
The VCF format stores sequence variations. For example:
## header line 1
## header line 2
## rest of header lines
#CHROM POS ID REF ALT
2
4370 rs9 G
A
:
:

QUAL
29

FILTER
.

INFO FORMAT Sample1 Sample2
NS=.. DP:HQ.. 0|0:48.. 0|0:46..

Table 2 gives a brief description for each column:
Table 2 - Columns of the VCF file

1
2
3
4

Name
CHROM
POS
ID
REF

5
6
7

ALT
QUAL
FILTER

Brief Description
The name of the sequence (a chromosome) on which the variation is being called.
The 1-based position of the variation on the given sequence.
The identifier of the variation
The reference base (or bases in the case of an Indel at the given position on the given
reference sequence.
The list of alternative alleles at this position.
A quality score associated with the inference of the given alleles.
A flag indicating which of a given set of filters the variation has passed.
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8
INFO
An extensible list of key-value pairs (fields) describing the variation.
9 FORMAT An (optional) extensible list of fields for describing the samples.
10 Samples (optional) For each sample, values are given for the fields listed in FORMAT.
Since we do not expect a large number of variations in each patient, VCF files are small files in the order
of a few Megabytes. They serve one of our core analysis assets in the next chapter.
Copy Number Variation Analysis
As with the somatic variation analysis, we have analyzed the processed files in order to identify CNVs.
This is also a per-patient analysis where we used VarScan2 as well. This step results in the CNVs for
each patient separately in a TAB-delimited format. It stores information about the copy numbers.
For example:
chrom
chr1
:
:

start
1489

stop
1588

num_positions
100

normal_depth
24.1

tumor_depth
10.6

log2_ratio
-1.182

gc_content
41.0

Table 3 gives a brief description for each column.
Table 3 - Columns of the CNV output file

1
2
3
4
5
6
7
8

Name
chrom
start
stop
num_positions
normal_depth
tumor_depth
log2_ratio
gc_content

Brief Description
Chromosome or reference name.
Start position of a contiguous copy number region (1-based).
Stop position of a contiguous copy number region (1-based).
Length of the region.
Average sequence depth in the normal.
Average sequence depth in the tumor.
Log-base-2 ratio of the tumor/normal depth ratio.
Proportion of GC bases in the region, between 0 and 100.

After that, we have processed the copy number data as following:





Filter the copy number calls by minimum coverage and/or region size.
Adjust raw copy number (log2) values for GC content.
Classify each region as amplification (gain), deletion (loss), or neutral based on your preferred
log2 thresholds.
Re-center raw copy number data if neutral segments are not on the log2=0 axis.

VarScan2 provides an implementation for this filtering/adjustment. Therefore, we have integrated it in our
pipeline. The file maps the repeated/deleted segments of the DNA to the corresponding chromosomes
and marks the start/end positions along with the log ratio of the copy number value. The raw output from
that phase of the pipeline is then smoothed and segmented using DNAcopy package in R [35]. The
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package analyses the data to detect larger regions with abnormal copy numbers. Another filtering that
we have applied is removing the copy number regions that have a log ratio in the range of [−0.5, 0.5].
This ensures that further analysis relies only on significant copy number values that denote a true
duplication or deletion. After that, we map the CNV regions to the list of known genes in RefSeq
database [36] with the goal of identifying the CNV genes.
Gene Annotation
The last step in this pipeline is to annotate the discovered mutations (SNPs and Indels) with regard to
genes and proteins. The idea is to define what aberrations fall into what exons of the known genes and
can change which protein. The obtain a comprehensive list of known genes along with their start/end
positions, we have used RefSeq database [36] which we obtained from UCSC genome browser. We
have used ANNOVAR v2016-02-01 to perform the annotation step [37].
By the end of the first data analysis pipeline, we have obtained the following for each patient:
1. A list of genes that have somatic mutations.
2. A list of genes that have CNVs.

RNA Sequencing
Similar to WES, RNA-Seq aims at obtaining short reads for the genomic features. However, instead of
capturing base pairs from the DNA samples, it operates on the RNA samples and quantifies presence of
mRNA at a given moment in time [38]. RNA-Seq facilitates the study of changes at the gene expression
in a given sample. Therefore, it is a tissue- and time-specific. Similar to the sequencing stages illustrated
in Figure 10, RNA-Seq follows the same stages except that we isolate RNAs instead of the exons. We
also study the gene expression only in the tumor tissue and compare it with the gene expression from
the same tissue in normal population.
Figure 14 of the downstream data analysis is similar to the analysis we did in the WES pipeline. However,
there is a number of differences due to the special nature of the RNA sequencing process. We explain
them in the next subsections.

Sequencing

Raw Reads

Quality Check

Alignment

Pre-processing

• Patient samples
• Illumina
Sequencing

• FASTQ files

• FASTQ.C

• Human Genome
19
• STAR Aligner

• Sorting
• Indexing

Figure 14 – RNA-Seq pipeline
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Gene Analyis
• Expression
• Fusion

Raw Reads and Quality Check
Similar to WES, data comes in raw text files in FASTQ format. For each patient, we have received a set
of FASTQ files for sequenced tissue. Sequencing of 8 patients (out of 16) were carried out from the
breast tissue. Sequencing for the other 8 patients were performed from the ovarian tissue. The reason
for that is that breast and ovarian cancers share common features. In addition, we have sequencing data
for 5 normal samples from the breast tissue of healthy women. The total size of all FASTQ files for all 21
patients is ~105 GB in a gzip compressed format. For the next pipeline phases, Linux scripts are
provided for each task on the project’s GitHub repository [25].

Figure 15 - Per base sequence quality for one RNA-Seq sample

The quality check summary reports showed no potential errors or warnings. Figure 15 shows an example
of the report generated by FASTQC for one of the RNA-Seq samples. Complete quality reports for all
patients can be found on the project’s GitHub repository under gene-analysis folder.
Alignment and Pre-processing
The next step in the pipeline is to map the short reads to the human genome. There is a crucial
difference from the WES reads alignment. Since RNA-Seq isolates RNAs instead of exons, generated
reads come from different exons regions. In other words, one read might not be mapped as one fragment
to the human genome; parts of the read may come from different exonic regions. Therefore, we have to
use an aligner that is aware of the splices. Therefore, we have used the STAR Aligner tool v020201 [39]
and mapped the reads to the human genome reference (Hg19) downloaded from UCSC genome
browser [28]. Figure 16 visualizes the spliced read alignment in RNA-Seq data.
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Figure 16 - Spliced read alignment to the human genome. Credit: edited from [40]

We have obtained the alignment file for each sample. The alignment files are in SAM format and the total
size of all SAM files for all 21 samples is ~300 GB. We have proceeded with the pre-processing of the
alignment data to have a faster analysis in the subsequent pipeline steps.
Gene Expression Analysis
Gene expression is the most basic level at which the genotype gives rise to the phenotype. In other
words, gene expression is affected by the genomic features at the DNA level and affects the observable
results such as the drug response in our clinical trial. The goal of this phase is to quantify the expression
levels of known genes in each of the given samples. To achieve this, we perform a per-sample analysis
calculating the number of reads that lie in known gene regions. The more reads we find in a known gene,
the more expression level this gene has. A number of normalization and statistical testing steps are
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performed afterwards to remove biases. Fortunately, existing software packages carry out this task
efficiently. We have used RSEM v1.2.31 [41] with Ensembl gene annotation database [42].
This phase results in the gene expression level for each sample separately in TAB-delimited format. It
stores information about the read counts for each gene. For example:

gene_id
ENSG003
:
:

transcript_id(s)
ENST049,ENST0731

length effective_length
2201.90 2096.31

expected_count
1803.00

TPM FPKM
9.67 20.07

Table 4 gives a brief description for each column:
Table 4 - Columns of the gene expression output file

1
2
3
4
5

Name
gene_id
transcript_id(s)
length
effective_length
expected_count1

6

TPM

7

FPKM2

Brief Description
The Ensembl gene ID of a known gene.
The Ensembl transcript ID (or IDs) corresponding to the gene ID above.
The transcript's sequence length.
It counts only the positions that can generate a valid fragment.
The sum of the posterior probability of each read comes from this transcript over
all reads.
It stands for Transcripts Per Million. It is a relative measure of transcript
abundance. The sum of all transcripts' TPM is 1 million.
It stands for Fragments Per Kilobase of transcript per Million mapped reads. It is
another relative measure of transcript abundance.

Each read aligning to a transcript has a probability of being generated from background noise, that’s
why it takes into account the probabilities. RSEM may filter some aligned low quality reads, the sum of
expected counts for all transcript are generally less than the total number of reads aligned.
1

2

FPKM is calculated as following:
𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒_𝑙𝑒𝑛𝑔𝑡ℎ𝑖
Let 𝑙 ̅ be the mean transcript length in a sample, 𝑙 ̅ = ∑𝑖 𝑇𝑃𝑀𝑖
, where 𝑖 is the transcript
6
10

number. We get, 𝐹𝑃𝐾𝑀𝑖 =

103
𝑙̅

× 𝑇𝑃𝑀𝑖

Gene Fusion Analysis
Recall from the previous chapter that two genes (or part) might fuse together forming a new gene that
ends with an unknown transcript. Therefore, the gene expression analysis cannot capture the gene
fusion phenomenon, since the new transcript maps to two different (and maybe distant) genes. This is
different from spliced alignment that takes into account different exons of a single gene. Fusion occurs
mostly due to genomic aberrations.
In this step of the pipeline, we have used Fusion Catcher v0.99.6a beta [43]. It searches for novel as well
as known somatic fusion genes, translocations, and chimeras in RNA-Seq data from disease samples.
translocation is a chromosome abnormality caused by rearrangement of parts between chromosomes.
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The tool shows very good detection rate for finding candidate somatic fusion genes. It stores information
about the candidate fused transcripts for each sample in a TAB-delimited file. Some of the columns are
shown below:
gene_1
ATAD2
:
:

gene_2
NPM1

fusion_description
cancer_tissues

spanning_pairs
5

fusion_sequence fused_transcript
..CTGA*GTCA..
..TGAAG*ATGATG..

Table 5 shows some of the columns of the Fusion Catcher output. The original full list of columns can be
found on the tool documentation files.
Table 5 - Columns of the gene fusion output file

1
2
3
4
5
6

Name
Brief Description
gene_1
Gene symbol of the 5' end fusion partner.
gene_2
Gene symbol of the 3' end fusion partner.
fusion_description Type of the fused gene referring to known database if it is a known fusion or
uniquely identified.
spanning_pairs
Count of pair-end reads supporting the fusion.
fusion_sequence The inferred fusion junction (the asterisk sign marks the junction point).
fused_transcript All possible known fused transcripts

Summary
In this chapter, we have covered the development stages of the data analysis pipelines. We have
developed and executed the necessary stages of obtaining genomic variation data as well as the gene
profiling data for the patients covered in our study. We have utilized a number of existing software tools
in different stages of the pipeline with the goal of optimizing the pipeline execution and obtaining reliable
results.
In the next chapter, we proceed to the next step of the study in which we mine the output files from the
developed pipelines to perform further analysis.
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Chapter 4: Data Analysis
So far, we have been able to transfer the raw sequencing data into meaningful per-patient genomic
features. We have obtained the somatic variation (SNP and Indel), CNV, gene expression and gene
fusion data. In addition, we know that patients under study are treated with Oral PI3kinase-inhibitor
(NVP-BKM120) in combination with the Oral PARP-inhibitor (Olaparib). Half of them responded to the
treatment and the other half did not respond. We consider the availability of WES and RNA-Seq data for
those patients. In this part of our study, we analyze the patients’ data obtained from the pipelines
illustrated in the previous chapter. The goal is to try answering the following question:
Can we identify candidate genomic biomarkers that drive drug resistance?
In other words, can we find aberrations in some genes of the non-responding patients that do not exist in
the responders? The nature of this question implies the following challenges:


Data Heterogeneity: as we have seen from the previous chapter, the datasets have different
formats and represent different biological meanings.



Feature selection: with the large number of features (genes) under study, we should use
appropriate feature selection or dimensionality reduction methods to identify only the features that
are biologically meaningful.



Small sample size: the number of samples is relatively small. This imposes a challenge in
applying machine learning and statistical methods.

Approach
The integrative analysis of genomic datasets comes in different flavors. We discuss the different
approaches in the next chapter. In our study, we have followed a data science approach. The motivation
is to extract knowledge from data. We aim at applying a wide range of techniques that guide our search
for a smaller feature list.
The hypothesis we followed in shown in Figure 17. The hypothesis is that the drug response is most
likely the result of the functional proteins produced by the tissue cells along with some other unknown
factor 𝜃1 . As we have shown in chapter 2, proteins are the ultimate results of gene expression. Therefore,
they are affected by the transcribed mRNAs that represent genes. Fused genes also play a nonnegligible role since they might lead to producing new proteins. Besides, the unknown factor 𝜃2 affects
the functional proteins. Gene expression and gene fusion are a result of the DNA features. Therefore,
aberrations in the DNA are considered the root cause of the drug response, without neglecting the third
unknown factor 𝜃3 .
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Figure 17 - Data Analysis Approach

Why did we include the unknown factors 𝜃𝑠? In general, the living organisms have a very complex
system of operation that cannot be modeled in a computation. Thus, being able to model many cellular
processes such as the gene expression and aberrations does not mean that we have modeled all cellular
processes. Without the loss of generality, Figure 17 captures all the data available in our study. In the
next sections, we explain our data mining and analysis steps and drive conclusions afterwards.

Data Crunching
In the previous chapter, we have seen how heterogeneous the data resulted from the pipelines is. To
perform any further analysis, we have to pre-process the data and construct meaningful data structures.
Therefore, we have formulated four matrices; one for each of the genomic features. We present the
process of obtaining them in the next subsections.
Gene Expression Matrix
The RNA-Seq data is tissue-specific. The data for the patients were sequenced from the breast for a
number of patients and the ovarian from the rest of them. The belief is that breast cancer and ovarian
cancer share many genotype features. Therefore, by mining the gene expression file for each patient, we
have obtained two separate matrices for each type of RNA sequencing: 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 for the breast samples
and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 for the ovarian samples. We construct the matrix as following:

𝑀1 =

𝑔1
𝑔2
𝑔𝑘
[𝑟

𝑝1

𝑝2

𝑝𝑛
⋯

⋮

⋱
⋯

⋮
]

Where 𝑔 stands for the gene, 𝑝 stands for the patient and 𝑟 stands for the drug response. The value at
the 𝑟 row is 1 if the patient responded to the drug and 0 if she belongs to the non-responders group. The
values in each cell of the matrix represents the gene expression value as either normalized read count or
transcript per million (TPM).
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Normalized Read Count Matrix
The value in each one of these cells represents the normalized read count of gene 𝑔𝑖 for patient 𝑝𝑗 for all
𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛], where k is the number of genes and n is the number of samples.
Transcript Per Million (TPM) Matrix
The value in each one of these cells represents the TPM value of gene 𝑔𝑖 for patient 𝑝𝑗 for all 𝑖 ∈
[1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. The TPM is a metric used to normalize for sequencing depth and gene
length. The software tool obtains it using the following operations:
1. Divide the read counts by the length of each gene in kilobases. This gives us reads per kilobase
(RPK).
2. Count up all the RPK values in a sample and divide this number by 1,000,000. This is the “per
million” scaling factor.
3. Divide the RPK values by the “per million” scaling factor. This gives the TPM.
Gene Fusion Matrix
From the RNA-Seq data, we have obtained the genes that showed fused transcripts for each patient. By
mining the gene fusion file for each patient, we construct the matrix 𝑀2 in the same way we constructed
𝑀1 as following:

𝑀2 =

𝑔1
𝑔2
𝑔𝑘
[𝑟

𝑝1

𝑝2

𝑝𝑛
⋯

⋮

⋱

⋮

⋯

]

1 𝑖𝑓 𝑡ℎ𝑒 𝑔𝑒𝑛𝑒 𝑖𝑠 𝑓𝑢𝑠𝑒𝑑
The value in each one of the cells = {
for each gene 𝑔𝑖 and patient 𝑝𝑗 , where 𝑖 ∈
0
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
[1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. We can notice that this matrix is very sparse containing a very large
number of zeros, since each patient has a very few number of fused genes (less than 10).
Somatic Variation Matrix
For each patient, we have obtained the annotated somatic variation file. The file maps mutations to the
corresponding genes from the RefSeq database [36]. We are only interested in variations that are
nonsynonymous. Therefore, we have filtered each patient’s file to opt out synonymous variations. Similar
to 𝑀1 and 𝑀2, we construct the following matrix:

𝑀3 =

𝑔1
𝑔2
𝑔𝑘
[𝑟

𝑝1

𝑝2

𝑝𝑛
⋯

⋮

⋱
⋯
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⋮
]

The value in each one of these cells is 1 if there is a nonsynonymous variation in gene 𝑔𝑖 for patient 𝑝𝑗
and 0 otherwise for all 𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. This matrix also has a high level of sparsity.
CNV Matrix
For each patient, we have obtained the annotated CNV file. Although the filtering done in the pipeline
seems firm, it resulted into thousands of CNV genes per patient. Of course, further analysis would fail if
we keep this number as it is for the reason that the number of features will be too large to have a
significant contribution to the drug response.
One further filtering step we have implemented is integrating the TPM value of a given gene for each
patient with the CNV values. Figure 18 illustrates this filtering step. For each patient, we sample the
values of genes TPM along the 𝑥 axis. We will then investigate only the genes in the first and last quartile.
We include the gene in our analysis only
if:




The gene lies in the first quartile
and has a negative log ratio of the
copy number, or
The gene lies in the last quartile
and has a positive log ratio of the
copy number.

In a nutshell, this filtering keep only the
genes that their CNV value is in the same
direction of their transcripts expression
Figure 18 - Filtering CNV by TPM value
value. The results is a reasonable number
of CNV genes per patient that their copy numbers are aligned with their expression levels (in the order of
100s). Similar to 𝑀1, 𝑀2 and 𝑀3, we contruct the matrix 𝑀4 as following:

𝑀4 =

𝑔1
𝑔2
𝑔𝑘
[𝑟

𝑝1

𝑝2

𝑝𝑛
⋯

⋮

⋱
⋯

⋮
]

The value in each one of these cells represents the log ratio of the copy number in gene 𝑔𝑖 for patient 𝑝𝑗
for all 𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. We set the value equals to 0 if the gene is opted out by previous
filtering. Figure 19 presents overall CNV profiles of responders and non-responder samples. This plot
shows accumulative sum of the CNV values for the genomic segments across all the chromosomes as
the Segment Gain Or Loss (SGOL) versus the chromosomes in both responders and non-responders
groups. The SGOL tells us patterns of copy number gain (positive) as green signal and patterns of copy
number loss (negative) as red signal. We can notice that most regions share close SGOL values
between the two groups. That means that copy number variations cannot be the sole cause for the drug
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response. That’s why an integrative analysis is required for this study. Plots are generated using
cghMCR package in R [44].

Figure 19 - CNV SGOL in responders and non-responders
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Feature Extraction
Referring to Figure 17, our goal is to identify aberrant genes that affected the drug response as
candidate biomarkers of drug resistance. The number of genes in each of the 𝑀1..4 matrices is 19,963.
This is a relatively large number compared to the number of samples we have – 16. Therefore, the first
step is to narrow down our search to a smaller number of genes. Our strategy is to go backward from the
drug response (phenotype) to the aberrant genes (genotype). First, we have extracted genes that their
expression levels differ significantly among the responder and non-responder samples. This computation
is known as the differential expression analysis. We hypothesize that genes that have the same (or
close) expression levels between the two groups are transcribed into proteins at the same level. Also,
genes that are differentially expressed are transcribed into proteins at different levels. This should be a
major contributing factor to the drug response. Second, we try to find a smaller set of genes that can
classify the two groups. In the next two subsections, we will see that it is not possible to find such a
reduced dimension features. In the following sections, we will illustrate how the analysis is steered from
that point.
Differential Expression Analysis
The idea of differential expression (DE) analysis is to identify transcripts and genes that have significantly
higher or lower level of abundance in the responder group compared to the non-responder group. To
perform DE analysis, we have used EBSeq package [45]. Filtering out with a false discovery rate (FDR)
of 0.05, we found that 𝟏𝟏𝟖𝟖 genes are differentially expressed between the responder and nonresponder groups in the breast sample. In the ovarian samples, we found that 𝟔𝟓𝟕 genes are
differentially expressed. It is important to note that:



There are 𝟓𝟎 differentially expressed genes in common between both tissues (breast and
ovarian). |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑏𝑟𝑒𝑎𝑠𝑡 | ∩ |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑜𝑣𝑎𝑟𝑖𝑎𝑛 | = 50
The total number of differentially expressed genes is 𝟏𝟐𝟏𝟔.
|𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑏𝑟𝑒𝑎𝑠𝑡 | ∪ |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑜𝑣𝑎𝑟𝑖𝑎𝑛 | = 1216

The result from the differential expression analysis reduced the size of 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 to have only 1188 genes
(dimensions), and the size of 𝑀1𝑜𝑣𝑟𝑎𝑖𝑎𝑛 to 657 genes (dimensions). However, this is still a large number
for performing further regression or classification analysis. To further reduce the number of genes, we
implemented a subsequent filtering step using the value of fold change.
Filtering with Fold Change
We removed the genes with low fold change (FC) from the two matrices (𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 ). Fold
change is a measure describing how much a gene is over-expressed or down-regulated between the two
groups. In order to decide the appropriate value of a threshold to use for filtering out low-concentration
genes, we plotted the histograms of log2 of FC of all genes with FDR< 0.05 that is shown in Figure 20.
We have noticed two small bumps around 1 and -1, which might be caused by an error. Therefore, we
filtered out genes that lie in the range [-2, 2]. Since it is log2 ratio, this means that we are opting out
genes with a fold change between 0.25 and 4 (0.25 < FC < 4). It turns out that there were 375 genes in
this range in 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 204 genes in this range in 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 . Therefore, the remaining genes that we
will focus on are 𝟖𝟏𝟑 genes in 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝟒𝟓𝟑 in the ovarian matrix 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 .
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Figure 20 - Histograms of gene expression fold change values

Figure 21 shows the heat maps of the expression levels of the top 50 differentially expressed genes in
both breast and ovarian samples. We can see significant over-expression in yellow in some genes of the
non-responders group.
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Figure 21 – Gene expression (log2 TPM). Left: breast samples. Right: ovarian samples
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Dimensionality Reduction
Given the differentially expressed genes 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 , the question now becomes: can we
classify the two groups and use them or some combination of them as a predictor of drug response?
Having a naked-eye look at 𝑀2 and 𝑀3 after removing the non-differentially expressed genes, we did not
see many aberrant genes among those DE genes as well. This motivated us to look for some
combination of the genes to serve as predictors.
The classical Principle Component Analysis (PCA) comes in handy for this purpose [46]. Figure 23
shows a plot of principle component 1 versus 2 and principle component 1 versus 3 in the breast
samples. Similarly, Error! Reference source not found. shows the same plots for the ovarian samples.

Figure 23 - PCA in breast samples

Figure 22 - PCA in ovarian samples
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In principle component analysis, the first principle component is a linear combination of all the feature set
(genes) that tries to capture the similarities between the data points. The second principle component
should be a linear combination of all the feature set that tries to differentiate (separate) the data points
above and below zero. Therefore, a successful PCA should show most data points in a small range over
PC 1 and a clear separation between the data points over PC 2 or 3. However, the above figures show
the exact opposite. Neither PC 1 could capture the similarities, nor PC 2 and 3 could separate between
the responder and non-responder groups.
This tells us that every trial to find a linear combination of the genes that can distinguish between the two
groups will fail. The reason for that might be the very small number of data points, compared to the
relatively large number of features. In addition, it tells us that separation between the responders and
non-responders based on the gene expression does not help identify the aberrant genes accountable for
the drug response. We can conclude that every patient has her own story of aberrations that led to
certain genes to be expressed at a certain level. Therefore, we need to find a higher level of abstraction
that can separate the two groups. Working on the small scale of DNA, RNA and gene expression is not
the best way to perform such analysis with a small number of patients.

Pathway Analysis
Let’s zoom out from investigating at the genome level and look at a higher level of cell functions. We
define molecular pathways to be a series of actions among molecules in a cell that leads to a certain cell
function. Figure 24 shows an abstraction of a simple pathway scenario. Cell receptors bind to signal
molecules triggering certain cell functions. For example, a gene regulatory network (GRN) is a collection
of molecular regulators that interact with each other and with other substances in the cell to govern the
gene expression levels of mRNA and proteins based on the signals received from the receptors. One
pathway typically engages more than one gene and one gene is a member of several pathways.

Figure 24 - Molecular pathways
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The idea now is to investigate what pathways are involved in the aberrant genes for each patient
separately, with the prospect that we can find common pathways among the non-responders that are not
found in the responders. At that point, we can focus our analysis on one or two of the most significant
pathways.

Figure 25 - Per patient pathway analysis

Figure 25 illustrates the pathway analysis that we performed. For each patient, we grouped together
genes that have any kind of variations. We queried each matrix (𝑀2 , 𝑀3 𝑎𝑛𝑑 𝑀4 ) after performing the
filtration steps discussed earlier (not all 19,963 genes) and produced a shortlist of aberrant genes for
each patient. Then, we have fetched their corresponding pathways. We have used KEGG pathways and
employed the Gene Set Enrichment Analysis tool for connecting to the KEGG pathways database [47,48].
After that, we constructed the pathway matrix 𝑃 and drug response vector 𝑅 as following:

𝑃=

𝑝1
𝑝2
[

𝑝𝑛

𝑝𝑡ℎ𝑦1

𝑝𝑡ℎ𝑦𝑚−1

𝑝𝑡ℎ𝑦2

𝑝𝑡ℎ𝑦𝑚

⋯
⋮

⋱

,

⋮

⋯

]
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𝑅= [:]

The value in each one of the 𝑃 cells is equal to:
𝑎𝑏𝑒𝑟𝑟𝑎𝑛𝑡 𝑔𝑒𝑛𝑒𝑠 𝑓𝑜𝑟 𝑝𝑖 ∩ 𝑔𝑒𝑛𝑒 𝑠𝑒𝑡 𝑖𝑛 𝑝𝑡ℎ𝑦𝑗
× 100.0
𝑔𝑒𝑛𝑒 𝑠𝑒𝑡 𝑖𝑛 𝑝𝑡ℎ𝑦𝑗
for all 𝑖 ∈ [1, 2, . . . , 𝑛] and 𝑗 ∈ [1, 2, . . . , 𝑚], where m is the number of enriched pathways (m=133). We set
the value equals to 0 if there are no aberrant genes in patient 𝑝𝑖 engaged in pathway 𝑝𝑡ℎ𝑦𝑗 . The union of
all pathways we got from the above queries was: 𝒎 = 𝟏𝟑𝟑. As an interpretation, the value in each cell of
𝑃 tells us how much a given pathway is engaged in the aberrations for each patient. A smaller value
means that there were few to no aberrations contributing to the drug response 𝑅 (0 𝑜𝑟 1). A larger value
means that aberrations in that pathway contribute significantly to the drug response. The choice of these
values will become justifiable in the next subsection.

Regression
Given the matrix 𝑃 , can we give a weight to each pathway that determines its effect on the drug
response? It turns out that regression is a convenient solution for this problem [49]. We represent the
matrix 𝑃 as the fixed input in the below illustration. Columns represent the pathways as features (𝑗 ∈
[1, 133]). Rows represent the patients’ data points. Values are as depicted in the previous subsection.
The objective of regression algorithms is to estimate the drug response 𝑅̂ using a coefficients vector 𝑊
as shown in Figure 26.

Figure 26 - Matrix setup for the regression analysis
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Regression algorithms try to choose values for the 𝑊 vector that minimize the following:
2
min ‖𝑃𝑊 − 𝑅‖2
𝑊

Figure 27 shows an example of a curve (blue) resulted from running regression on a sample of data
points that have only one feature 𝑝0 . However, we have 133 features in our matrix 𝑃 and only 16
samples (data point). The choice of which regression algorithm to use is very critical in the drug response
estimation. We want to obtain few pathways out of 133 pathways that discriminates the responding and
non-responding groups. A common pitfall results from overfitting the curve to the data points – typically
when the blue line tries to pass through every data point. Therefore, we decided to use Lasso regression.

Figure 27 - Regression example in one dimension

Lasso
Lasso (Least Absolute Shrinkage and Selection Operator) penalizes the absolute size of the regression
coefficient [50]. In addition, it is capable of reducing the variability and improving the accuracy of linear
regression models. Lasso avoids overfitting by adding a regularization parameter to the equation above
as following:
min ‖𝑃𝑊 − 𝑅‖2 2 + 𝛼 ‖𝑊‖1
𝑊

The added term is called L1 regularization. Another advantage of the L1 regularization is that it leads to
penalizing (or equivalently constraining the sum of the absolute values of the estimates) values which
causes some of the parameter estimates to turn out exactly zero. Larger the penalty applied, further the
estimates get shrunk towards absolute zero. This results to variable selection out of given n variables. So,
running the Lasso regression with different values of 𝛼 will lead to many pathways to be cancelled out
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(given a coefficient of zero). Running Lasso on our matrix using different values of 𝛼 results in the
following coefficients (Table 6)
Table 6 – Coefficient values at different values of 𝜶

𝜶

rss

𝟏𝟎−𝟏𝟓
𝟏𝟎−𝟏𝟎
𝟏𝟎−𝟖
𝟏𝟎−𝟓
𝟏𝟎−𝟒
𝟏𝟎−𝟑
𝟏𝟎−𝟐
1
5
10

0.96
0.96
0.96
0.96
1
1.7
3.6
37
37
37

intercept coef_x_1 coef_x_2 coef_x_3
0.22
0.22
0.22
0.5
0.9
1.3
1.8
0.038
0.038
0.038

0.6
0.6
0.6
0.2
0.1
0.01
-0.55
0
0
0

-0.37
-0.37
-0.37
-0.13
-0.048
0
0
0
0
0

0.0016
0.0016
0.0016
0
0
0
0
0
0
0

…

coef_x_133

…
…
…
…
…
…
…
…
…
…

10−8
10−8
10−8
10−6
10−6
10−3
10−3
0
0
0

Cancelled
Pathways
6
6
6
103
115
116
120
133
133
133

We have tried the Lasso regression with different weights of 𝛼 to decide an appropriate value that can be
used. As we can see in Table 6, the largest values of 𝛼 made all the coefficients equal to 0. The smallest
values of 𝛼 only cancelled 6 pathways leaving us with 127 pathways to investigate, which is a large
number. We have chosen the values of 𝛼 in the middle rows (highlighted) as they cancel a large number
of pathways, but leave us with the most important pathways that have an effect on the drug response.
We can deduce that positive coefficients mean that the corresponding pathways promote the drug
response since they are trying to predict a value of 𝑅̂ close to 𝑅 = 1. Similarly, negative coefficients can
be thought of promoting resistance as they are trying to predict a value of 𝑅̂ close to 𝑅 = 0. Table 7
shows the pathways that are not cancelled along with their corresponding coefficients for each value of
the chosen alphas. We have highlighted the pathways that drive drug response with blue and pathways
that drive resistance with red. Pathways that are not highlighted are opted out from our further analysis
since they are either not related to gene regulations or their coefficients are mostly zero for 𝛼 values.
Now, we can manually investigate the pathways that promote resistance and filter out those that are not
related to cancer. For this step, we have looked at each pathway description on the KEGG database.
Four of these pathways have biological meaningful fictions regarding tumor growth and are most likely
related to the drug resistance in our study:
1. KEGG_CELL_CYCLE
Brief description: Mitotic cell cycle progression is accomplished through a reproducible sequence of
events, DNA replication (S phase) and mitosis (M phase) separated temporally by gaps known as G1
and G2 phases.
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_CELL_CYCLE.html
2. KEGG_HOMOLOGOUS_RECOMBINATION
Brief description: Homologous recombination (HR) is essential for the accurate repair of DNA double-
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strand breaks (DSBs), potentially lethal lesions.
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_HOMOLOGOUS_RECOMBINATION.html
3. KEGG_INOSITOL_PHOSPHATE_METABOLISM
Brief description: Inositol phosphate metabolism.
Link:
http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_INOSITOL_PHOSPHATE_METABOLISM.html

4. KEGG_TGF_BETA_SIGNALING_PATHWAY
Brief description: A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation
and migration are regulated by TGF-beta family members.
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_TGF_BETA_SIGNALING_PATHWAY.html
Table 7 - Pathways from Lasso regression

Pathway ID (KEGG)
KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION
KEGG_N_GLYCAN_BIOSYNTHESIS
KEGG_PPAR_SIGNALING_PATHWAY
KEGG_FOCAL_ADHESION
KEGG_INSULIN_SIGNALING_PATHWAY
KEGG_OXIDATIVE_PHOSPHORYLATION
KEGG_RNA_DEGRADATION
KEGG_INOSITOL_PHOSPHATE_METABOLISM
KEGG_LONG_TERM_POTENTIATION
KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS
KEGG_TGF_BETA_SIGNALING_PATHWAY
KEGG_ADHERENS_JUNCTION
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM
KEGG_OOCYTE_MEIOSIS
KEGG_TYROSINE_METABOLISM
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY
KEGG_GLIOMA
KEGG_CELL_CYCLE
KEGG_RENAL_CELL_CARCINOMA
KEGG_VIBRIO_CHOLERAE_INFECTION
KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS
KEGG_SPLICEOSOME
KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM
KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR
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coef
at 𝜶 =
𝟏𝟎−𝟓
0.0425
-0.019
-0.001
-0.020
0.043
-0.027

0.069
0.066
0.008
-0.051
0.008
-0.001
0.071
0
-0.078
0.072
0.0015
0.0037
0.0054
-0.040
0.0001
-0.035
0.0320
0
-0.022
-0.054
-0.002
-0.052

coef
coef
coef
at 𝜶 = at 𝜶 = at 𝜶 =
𝟏𝟎−𝟒
𝟏𝟎−𝟑
𝟏𝟎−𝟐
0.039
0.014 0.0519
0
0
0
0
0
0
0
0
0
0
0
0
-0.02
-0.01
-0.02
0.0863 0.090 0.0480
0.105
0.153
0.036
0
0
0
-0.069 -0.088
0
0
0.0005 0.005
-0.008 -0.018 -0.017
0.081
0.085
0.061
0.0003
0
0
-0.043 -0.015
0
0.0625 0.0372
0
0
0
0
0
0
0
0
0
0
-0.048 -0.019
0
0
0
0
-0.038 -0.017 -0.022
0
0
0
0.0185 0.0052 0.0051
0
0
0
-0.062 -0.065 -0.021
0
0
0
-0.058 -0.068 -0.031

0
0.0688
0.0427 0.0624
-0.004 -0.023
0
0
0.0128 0.0060 0.0033 0.0032
0
0
0
0.0009
0
0
0
-0.004

KEGG_PURINE_METABOLISM
KEGG_HOMOLOGOUS_RECOMBINATION
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS
KEGG_OLFACTORY_TRANSDUCTION
KEGG_VEGF_SIGNALING_PATHWAY

Backtracking
Now that we have narrowed down our research to four pathways, the next step has been to look back at
the aberrant genes for each non-responding patient, which engage in these four pathways. We compute
the overlap matrix as following:
𝑝1
CELL CYC __
𝑂𝑣𝑒𝑟𝑙𝑎𝑝 = HOMOLOG __
INOSITOL __
[ TGF BETA __

… 𝑝𝑛
…
…
…
]
…

Each cell of the overlap matrix represents a vector of aberrant genes for patient 𝑝𝑖 that are a subset of
the corresponding pathway. Then, we have looked at each row of this matrix and identify the most
frequent genes that appear in all non-responding patients, but not appearing in the responding group.
Then, we have ordered genes in a descending order from most frequent to least frequent. Results are
presented in Table 8.
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Table 8 - Genes driving drug resistance

Gene

Pathway

Significance to
drug resistance

PIK3CB

Inositol
phosphate
metabolism

High

PIK3C2B

Inositol
phosphate
metabolism

High

RAD52

Homologous
recombination

High

RPA4

Homologous
recombination

High

PITX2

TGF-beta
signaling
pathway

High

MCM3

Cell cycle

High

MRE11A

Homologous
recombination

Medium

POLD3

Homologous
recombination

Medium

EP300

Cell cycle

Medium

Biological Validation
PIK3CB (Phosphatidylinositol-4,5-Bisphosphate 3Kinase Catalytic Subunit Beta) is a Protein Coding
gene. PI 3-Kinases (phosphoinositide 3-kinases, PI
3-Ks) are a family of lipid kinases capable of
phosphorylating the 3'OH of the inositol ring of
phosphoinositides. They are responsible for
coordinating a diverse range of cell functions
including proliferation and survival.
PIK3C2B (Phosphatidylinositol-4-Phosphate 3Kinase Catalytic Subunit Type 2 Beta) is a Protein
Coding gene. It belongs to the same family as
PIK3CB.
RAD52 (RAD52 Homolog, DNA Repair Protein) is a
Protein Coding gene. Involved in double-stranded
break repair. It plays a central role in genetic
recombination and DNA repair by promoting the
annealing of complementary single-stranded DNA
and by stimulation of the RAD51 recombinase.
RPA4 (Replication Protein A4) is a Protein Coding
gene. As part of the alternative replication protein A
complex, aRPA, binds single-stranded DNA and
probably plays a role in DNA repair.
PITX2 (Paired Like Homeodomain 2) is a Protein
Coding gene. It controls cell proliferation in a tissuespecific manner and is involved in morphogenesis.
MCM3 (Minichromosome Maintenance Complex
Component 3) is a Protein Coding gene. It acts as
component of the MCM2-7 complex (MCM complex)
which is the putative replicative helicase essential for
once per cell cycle DNA replication initiation and
elongation in eukaryotic cells.
MRE11A (MRE11 Homolog A, Double Strand Break
Repair Nuclease) is a Protein Coding gene. It is a
component of the MRN complex, which plays a
central role in double-strand break (DSB) repair, DNA
recombination, maintenance of telomere integrity and
meiosis.
POLD3 (DNA Polymerase Delta 3, Accessory
Subunit) is a Protein Coding gene. It is required for
optimal DNA polymerase delta activity.
EP300 (E1A Binding Protein P300) is a Protein
Coding gene. Bromodomains (BRDs) are epigenetic
reader domains that selectively recognize acetylated
lysine residues on the tails of histone proteins, and
are the only known protein modules that can target
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INPPL1

Inositol
phosphate
metabolism

Medium

EP300

TGF-beta
signaling
pathway

Medium

RAD54L
Homologous
MUS81
recombination
BLM
ORC6
STAG1
ATR
CCND2
TFDP2
YWHAB
Cell cycle
CHEK1
ORC4
HDAC1
WEE2
CDKN2C
CCNE1
PLCZ1
PLCB1
INPP5E
Inositol
INPP5B
phosphate
metabolism
INPP4A
ITPK1
PLCG1
ID1
PPP2R1B
TGF-beta
BMP2
signaling
pathway
BMP7
ACVR1

acetylated lysine residues.
INPPL1 (Inositol Polyphosphate Phosphatase Like 1)
is a Protein Coding gene. It plays a central role in
regulation of PI3K-dependent insulin signaling,
although the precise molecular mechanisms and
signaling pathways remain unclear.
EP300 (E1A Binding Protein P300) is a Protein
Coding gene. Bromodomains (BRDs) are epigenetic
reader domains that selectively recognize acetylated
lysine residues on the tails of histone proteins, and
are the only known protein modules that can target
acetylated lysine residues.

Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
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Chapter 5: Discussion
Cancer is a complicated disease and curing it requires enormous amount of efforts in many different
directions. Some researchers have been focusing on understanding the disease development. Others
have been studying possible treatments. In all directions, the ground truth is that the study of cancer
genomics speeds up our progress toward curing the disease. Although every cancer patient has his/her
own case of genomic aberrations that caused the disease, a comprehensive analysis of a large number
of patients helps us find common aberrations that will serve as a key point-of-focus for further studies.
Given the genomic data of phase-1 clinical trial on 35 patients, our research question was to find
candidate biomarkers for the drug resistance using limited number of samples (which is the case for all
clinical trial studies). We run an unbiased, data driven and personalized approach to shed light on driver
pathways and genes for drug resistance. Our story of following the data science approach can be
described as looking for a needle in a haystack. Over 5 terabytes of data have been analyzed to extract
a summary of the candidate genes that drive drug resistance when aberrant. Interestingly, the final
results – the 4 pathways and the genes with higher score in Table 8 – potentially showed a biological
meaning associated with drug response. We believe that aberrations in these genes can significantly
contribute to the drug resistance shown in the given dataset. Of course, the wet lab validation of the
candidate biomarker is required. Our goal is to generate a short list of candidate biomarker to facilitate
the process of biomarker discovery.
During the lifetime of this study, we have faced a number of challenges that we had to deal with.
1. Big data nature: as we have seen in chapter 3, genomic data is very large in size. This nature
implies a difficulty in designing and running automated pipelines. Computations takes a long time
and if for some reason running computations failed, we do not want to re-run the whole pipeline
from the beginning; that would be inefficient and time consuming. We have coded scripts that
automate the pipeline execution.
2. Small number of samples: even though the size of the data is very large, they only represent a
small number of samples. That’s why conventional statistical analysis and machine learning
techniques do not work. Using prior knowledge (pathways) and personalized approach (per
patient analysis), we were able to tackle the problem from a different angle.
3. Data heterogeneity: the genomic features under study come from different resources and
represent different meanings. In addition, they come in different file formats. Thus, we had to preprocess the data to come up with an abstract way of presenting them – using matrices.
4. Integrative analysis: due to the small number of samples and the fact that there is many missing
information (represented as 𝜃 parameters), running our analysis on the micro-level of aberrant
genes failed to classify the two groups. Consequently, we had to zoom out into a bigger view on
the genomic features – pathways. Running regression on pathways was a successful trial in our
case.
For the above challenges, conventional methods do not perform well. Linear and non-linear
dimensionality reduction methods cannot find a smaller set of genes that do the classification. Applying
regression on aberrant genes fails since the number of genes is very large relative to the number of
samples. Perhaps the biggest limitation we have is the small number of samples that prevent us from
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generalizing conclusions. The main advantage of the proposed approach is that analysis was done per
patient. This means that we can gain a higher level of confidence with the results. Moreover, the datadriven and unbiased approach that does not make any assumption about the distributions of the data
offer a strong aspect on solving such problems. On the flip side, this approach might not be the best one
to follow if the number of samples is very large, since we will end up with a large number of pathways as
features.
This study has generated tons of data that can be further investigated by clinicians and specialists. We
can summarize our contribution in this study in the following points:
1. Developing the data analysis pipelines that anatomize raw sequencing data into meaningful
information.
2. Researching and implementing different data analysis techniques – borrowed from the data
science domain – on the processed data.
3. Developing a method by integrating prior knowledge (from pathways) with genomics data of
limited number of sample to identify biologically meaningful candidate biomarkers. Finding clues
to the main research question: “can we identify candidate genomic biomarkers that drive drug
resistance?”, and suggesting answers.

Future Work
With advances in sequencing technologies and the availability of an increasing amount of high
throughput genomics data, the use of advanced computational methods to analyze, integrate, and mine
the huge amount of genomics data is an absolute necessity. We see this study as one building block
toward a broader integrative analysis of genomics data that will also include microRNA, ChIP-Seq and
Methylation data. Our future research steps are:
1.
2.
3.
4.

Cross-validation of the results using other software packages in the pipeline analysis.
Investigate the prevalence of the identified candidate biomarkers using TCGA data.
Integrate the pathway analysis part into the pipelines.
Develop a fully-automated pipeline that takes raw sequencing data and perform all the analysis in
the steps followed in this study.
5. Include clinical data such as age, race and tumor stage into our feature set.
To conclude, our research focus would be on optimizing the computational pipelines and enhancing the
unbiased and data-driven analysis approach.
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List of Abbreviations
CNV – Copy Number Variation
DE – Differential Expression
DNA – Deoxyribonucleic Acid
ER – Estrogen Receptors
FC – Fold Change
FDR – False Discovery Rate
FPKM – Fragments Per Kilobase of transcript per Million mapped reads.
GRN – Gene Regulatory Network
Lasso – Least Absolute Shrinkage and Selection Operator
PCA – Principle Component Analysis
PR – Progesterone Receptor
RNA – Ribonucleic Acid
RNA-Seq – RNA Sequencing
RPK – Reads Per Kilobase
SAM – Sequence Alignment/Mapping
SGOL – Segment Gain Or Loss
SNP – Single Nucleotide Polymorphism
TCGA – The Cancer Genome Atlas
TNBC – Triple Negative Breast Cancer
TPM – Transcripts Per Million
VCF – Varian Calling Format
WES – Whole Exome Sequencing
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